Geneva: Gavi, the Vaccine Alliance announced that it had signed an agreement with Moderna related to the supply of COVID-19 vaccines to lower-income countries supported by the Gavi COVAX Advance Market Commitment (AMC).
Under the agreement, Gavi and Moderna agree to cancel the remaining volumes under their previous agreement in 2022 and establish a framework for lower-income countries to access doses of variant-containing vaccine (VCV) beginning in 2023. Gavi will have the right to access up to 100 million VCV doses, at Moderna’s lowest-tiered price, on behalf of AMC participants.
“This agreement with Moderna represents a critical step for equitable access, helping COVAX adjust its portfolio to current demand and ensuring lower-income countries have access to variant-containing vaccines to use where appropriate,” said Dr Seth Berkley, CEO, Gavi, which leads procurement and delivery at scale for COVAX.
“Gavi and our COVAX partners have been pivotal in ensuring the global supply of COVID-19 vaccines, leading the largest and most rapid vaccine rollout in history,’ said Stéphane Bancel, Chief Executive Officer, Moderna. “We are proud of our role in this endeavour and will continue to support COVAX’s mission to ensure broad, affordable, and equitable access to COVID-19 vaccines across low-and middle-income countries as we move towards a world where COVID-19 is endemic.”
A key element to COVAX’s ability to deploy COVID-19 vaccines at a historically high rate has been its ability to adapt to an unpredictable and rapidly changing pandemic environment. This latest agreement is part of an ongoing effort to actively manage COVAX’s portfolio to meet countries’ evolving needs and be prepared for unexpected future scenarios by rephasing, resizing and updating supply agreements with manufacturers and donors.
Recognising that countries’ needs are still constantly changing, COVAX has also updated its allocation model so that AMC participants can now request – and be rapidly allocated – doses at any time.